. Author manuscript; available in PMC: 2010 Nov 3.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2009 Nov 3;18(11):2807–2813. doi: 10.1158/1055-9965.EPI-09-0472

Table 4.

Association between low serum cholesterol concentration (< 200 versus ≥ 200 mg/dL) and prostate cancer by treatment arm of the trial, Prostate Cancer Prevention Trial

Treatment arm	No prostate cancer	Prostate cancer
Treatment arm	No prostate cancer	Total	Gleason 2-6	Gleason 7-10	Gleason 8-10
Finasteride
N (low/high cholesterol) OR_{multivariable-adjusted}^* 95% CI	1,753 / 2,738	370 / 503 1.13 (0.97, 1.31)	237 / 331 1.11 (0.92, 1.32)	133 / 172 1.16 (0.92, 1.47)	38 / 55 1.03 (0.68, 1.57)
Placebo
N (low/high cholesterol) OR_{multivariable-adjusted}^* 95% CI	1,693 / 2,642	477 / 774 0.97 (0.85, 1.11)	389 / 604 1.03 (0.89, 1.18)	88 / 170 0.78 (0.60, 1.02)	13 / 46^** 0.41 (0.22, 0.77)
P-interaction		0.12	0.52	0.03	0.02

Adjusted for age, race, family history, BMI, diabetes, regular aspirin use, and history of heart attack.

^**

The expected number of Gleason 8-10 cases in the low cholesterol group is 30 based on the age- and race- adjusted proportion in the high cholesterol group.